A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition
- PMID: 31363847
- DOI: 10.1007/s00415-019-09489-5
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition
Abstract
Secondary progressive multiple sclerosis (SPMS) is the second most common form of multiple sclerosis (MS). One in two relapse remitting multiple sclerosis (RRMS) patients will develop SPMS within 15 years and up to two-thirds after 30 years, leading to a progressive decrease of neurological function and limitation of daily activities. Nevertheless, the SPMS diagnosis is often established retrospectively and delayed up to 3 years due to several patient- and clinician-related factors. Definitive clinical diagnostic criteria are lacking and research is currently ongoing to identify imaging and biochemical biomarkers. As new therapies are introduced, early SPMS diagnosis may represent a window of opportunity for intervention. New approaches, endpoints or technologies could help physicians establishing a diagnosis. Here, we review SPMS in relation to its diagnostic and definition challenges and current screening techniques and tools.
Keywords: Definition; Diagnosis; Endpoints; SPMS; Screening.
Similar articles
-
Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.Mult Scler Relat Disord. 2021 May;50:102858. doi: 10.1016/j.msard.2021.102858. Epub 2021 Feb 23. Mult Scler Relat Disord. 2021. PMID: 33799068
-
Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.Mult Scler Relat Disord. 2021 Nov;56:103319. doi: 10.1016/j.msard.2021.103319. Epub 2021 Oct 10. Mult Scler Relat Disord. 2021. PMID: 34666241
-
Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.Mult Scler Relat Disord. 2021 May;50:102778. doi: 10.1016/j.msard.2021.102778. Epub 2021 Jan 28. Mult Scler Relat Disord. 2021. PMID: 33592384 Review.
-
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.Mult Scler. 2021 Apr;27(4):579-584. doi: 10.1177/1352458520924586. Epub 2020 Jun 2. Mult Scler. 2021. PMID: 32484381
-
A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.J Steroid Biochem Mol Biol. 2016 Nov;164:254-257. doi: 10.1016/j.jsbmb.2015.11.009. Epub 2015 Nov 17. J Steroid Biochem Mol Biol. 2016. PMID: 26598277 Review.
Cited by
-
MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression.J Clin Med. 2022 Jul 28;11(15):4401. doi: 10.3390/jcm11154401. J Clin Med. 2022. PMID: 35956018 Free PMC article. Review.
-
Siponimod: A Review in Secondary Progressive Multiple Sclerosis.CNS Drugs. 2020 Nov;34(11):1191-1200. doi: 10.1007/s40263-020-00771-z. Epub 2020 Oct 27. CNS Drugs. 2020. PMID: 33108633 Free PMC article. Review.
-
The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice.Front Neurosci. 2020 Oct 26;14:582046. doi: 10.3389/fnins.2020.582046. eCollection 2020. Front Neurosci. 2020. PMID: 33192268 Free PMC article.
-
Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment-A Literature Review.J Clin Med. 2024 Mar 11;13(6):1598. doi: 10.3390/jcm13061598. J Clin Med. 2024. PMID: 38541824 Free PMC article. Review.
-
Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis.Int J Mol Sci. 2025 Apr 20;26(8):3889. doi: 10.3390/ijms26083889. Int J Mol Sci. 2025. PMID: 40332781 Free PMC article. Review.
References
-
- Khurana V SH, Medin J, Adlard N (2018) Estimated prevalence of diagnosed secondary progressive multiple sclerosis in the Americas and Europe: results from a systematic literature search. In: Paper presented at the poster presented at the American Academy of Neurology Annual Meeting, 21–27 April 2018, Los Angeles, CA, USA.
-
- Multiple Sclerosis International Federation (MSIF). (2013) Atlas of MS 2013. https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf . Accessed 24 Apr 2019
-
- English C, Aloi JJ (2015) New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther 37(4):691–715. https://doi.org/10.1016/j.clinthera.2015.03.001 - DOI - PubMed
-
- Coret F, Perez-Miralles FC, Gascon F et al (2018) Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. Mult Scler J Exp Transl Clin 4(2):2055217318783347. https://doi.org/10.1177/2055217318783347 - DOI - PubMed - PMC
-
- Scalfari A, Neuhaus A, Daumer M et al (2014) Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85(1):67–75. https://doi.org/10.1136/jnnp-2012-304333 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials